Physician profile
Teodora A Schellato
NPI 1184839698
$41,289.69
in general payments reported to CMS, 2019-2025
59 companies · $2,240 in 2025
The $2,240 reported for 2025 was more than what 82% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,586 · 2020: $7,834 · 2021: $5,833 · 2022: $7,814 · 2023: $7,260 · 2024: $6,722 · 2025: $2,240.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $8,730 · Food and Beverage: $7,427 · Education: $64.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $8,730.00 |
| Food and Beverage | $7,427.33 |
| Education | $64.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $21,758.60 | 2021-2025 | Interstim |
| Medtronic USA, INC. | $9,479.03 | 2019-2020 | |
| Dendreon Pharmaceuticals LLC | $1,186.43 | 2019-2025 | Provenge |
| Sumitomo Pharma America, INC. | $1,059.82 | 2023-2025 | Gemtesa, Orgovyx |
| Astellas Pharma US INC | $831.27 | 2019-2025 | Xtandi, Veozah, Myrbetriq |
| Abbvie INC. | $696.17 | 2022-2025 | Botox |
| Janssen Biotech, INC. | $569.49 | 2019-2025 | Erleada |
| Myovant Sciences INC. | $533.36 | 2021-2022 | |
| Teleflex LLC | $503.09 | 2021-2025 | Urolift, Barrigel, Solesta |
| Urogen Pharma, INC. | $418.93 | 2022-2025 | Jelmyto |
| Bayer Healthcare Pharmaceuticals INC. | $345.27 | 2019-2025 | |
| 180 Medical, INC. | $262.32 | 2019-2022 | |
| Axonics, INC. | $231.10 | 2021-2024 | Bulkamid, Axonics |
| Pfizer INC. | $229.03 | 2019-2025 | |
| Tolmar Pharmaceuticals, INC. | $209.80 | 2019-2022 |
Show all 59 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Teodora Schellato listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.